 |
8 Diseases |  |
0 Trials |
|
0 Trials |  |
48 News |  |
- || AADvac1 / Axon Neurosci
P2 data, Retrospective data, Journal: Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical (Pubmed Central) - Jan 22, 2024
P2
In the subgroup of ML imputed or CSF identified A+T+, AADvac1 slowed AD-related decline in an antibody-dependent manner. Larger anti-tau trials are warranted.
- || AADvac1 / Axon Neurosci
P3 data: When will be release aadvac1 phase 3 results? (Twitter) - Mar 9, 2022
- AADvac1 / Axon Neurosci
The mechanism of action and efficacy of AADvac1, an active immunotherapy against pathological tau protein, in a placebo-controlled randomised phase 2 study (Convention Ctr - 605/607) - Aug 2, 2021 - Abstract #AAIC2021AAIC_1819;
Larger anti-tau trials are warranted. These findings suggest that AADvac1 offers an efficacious approach to the treatment of neurofibrillary degeneration in AD with well-defined mechanism of action.
- ACmab1 / Axon Neurosci, AADvac1 / Axon Neurosci
[VIRTUAL] AXON Neuroscience () - May 31, 2021 - Abstract #BIO2021BIO_256;
The company has successfully completed the preclinical phase for its lead COVID-19 asset: ACmab1 (therapeutic antibodies against COVID-19). This confirmed superior characteristics of ACmab1 vs. other therapies, in terms of efficacy on new mutated variants, method of administration, as well as its significantly lower pricing potential.
- | DC8E8 / Axon Neurosci, AADvac1 / Axon Neurosci
Journal: Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation. (Pubmed Central) - May 29, 2021
This promoting activity requires the presence of the Fc-domain of the antibodies.The IgG1 isotype of AX004 showed greater ability to promote tau uptake compared to the IgG4 isotype, while none of the antibody-tau complexes provoked increased pro-inflammatory activity of microglia. Our data suggest that IgG1 has better suitability for therapeutic development.
- || donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
Review, Journal: Alzheimer's disease: Recent treatment strategies. (Pubmed Central) - May 15, 2021
Current treatment for AD (donepezil, galantamine, rivastigmine and memantine) is only symptomatic and has modest benefits...Even the positive findings presented by Biogen on Aducanumab are not entirely clear and further data is necessary to confirm its validity...Four monoclonal antibodies anti-tau (Gosuranemab, Tilavonemab, Semorinemab and Zagotenemab) and one anti-tau vaccine (AADvac1) have reached phase II, so far. In this review, we discuss the potential disease-modifying agents tested in clinical trials and update the information of drugs that are still under clinical evaluation.
- | AADvac1 / Axon Neurosci
Journal, IO Biomarker: AADvac1, an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development. (Pubmed Central) - Aug 4, 2020
Treatment with AADvac1 proved to be remarkably safe, with injection site reactions being the only adverse event tied to treatment. AADvac1 is currently being investigated in a phase 2 study in Alzheimer's disease, and a phase 1 study in non-fluent primary progressive aphasia, a neurodegenerative disorder with a high tau pathology component.
- AADvac1 / Axon Neurosci
[VIRTUAL] AADVAC1 – THE FIRST TAU VACCINE FOR ALZHEIMER´S DISEASE: RESULTS FROM PHASE II STUDY (Hall E) - Feb 22, 2020 - Abstract #AATADPD2020AAT_ADPD_963;
Conclusions This phase 2 study showed a disease-modifying effect of AADvac1 in Alzheimer’s Disease by combination of several biomarkers and clinical outcomes. The study successfully met the primary endpoint, confirming the exceptional safety profile of the vaccine, and showed its outstanding immunogenicity.
- |||| AADvac1 / Axon Neurosci
Trial completion: ADAMANT: 24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Nov 15, 2019
P2, N=208, Completed, Sponsor: Axon Neuroscience SE
The study successfully met the primary endpoint, confirming the exceptional safety profile of the vaccine, and showed its outstanding immunogenicity. Active, not recruiting --> Completed
- || AADvac1 / Axon Neurosci
Enrollment closed, Trial completion date, Trial primary completion date: AIDA: A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia (clinicaltrials.gov) - Nov 15, 2019
P1, N=33, Active, not recruiting, Sponsor: Axon Neuroscience SE
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Jul 2020 --> Nov 2020 | Trial primary completion date: Jul 2020 --> Nov 2020
- | RO6926496 / Roche, AADvac1 / Axon Neuroscience
Clinical, Journal: Harnessing Neuroplasticity: Modern Approaches and Clinical Future. (Pubmed Central) - Oct 18, 2019
Lastly, mechanical stimulation of brain regions through therapeutic hypothermia or deep brain stimulation (DBS) have given insight on the larger scale of neuroplasticity within the nervous system. Harnessing neuroplasticity may not only offer an arm in the vast arsenal of approaches being taken to tackle neurological disorders, such as neurodegenerative diseases, but from ample evidence, it also has major implications in neuropsychological disorders.
- AADvac1 / Axon Neurosci
AADVAC1 TAU VACCINE COMPLETING THE PHASE 2 STUDY: A PARADIGM SHIFT FOR THE AD TREATMENT HYPOTHESIS () - Oct 16, 2019 - Abstract #CTAD2019CTAD_17;
Harnessing neuroplasticity may not only offer an arm in the vast arsenal of approaches being taken to tackle neurological disorders, such as neurodegenerative diseases, but from ample evidence, it also has major implications in neuropsychological disorders. The AADvac1 phase 2 study is on track to confirm the favorable safety profile and high immunogenicity, and is powered to confirm the compelling efficacy signals observed in the phase 1 Study.
- | AADvac1 / Axon Neuroscience
P1 data, Journal: FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease. (Pubmed Central) - Sep 1, 2019
P1
The tendency towards slower atrophy in MRI evaluation and less of a decline in cognitive assessment in patients with high titres is encouraging. Further trials are required to expand the safety database and to establish proof of clinical efficacy of AADvac1.
- ||| AADvac1 / Axon Neurosci
Enrollment closed, Trial primary completion date: ADAMANT: 24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Aug 29, 2017
P2, N=208, Active, not recruiting, Sponsor: Axon Neuroscience SE
Further trials are required to expand the safety database and to establish proof of clinical efficacy of AADvac1. Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2019 --> Jun 2019
- AADvac1 / Axon Neurosci
Enrollment open: AIDA: A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia (clinicaltrials.gov) - Aug 29, 2017
P1, N=30, Recruiting, Sponsor: Axon Neuroscience SE
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2019 --> Jun 2019 Not yet recruiting --> Recruiting
- | AADvac1 / Axon Neurosci
New P1 trial: AIDA: A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia (clinicaltrials.gov) - Jun 5, 2017
P1, N=30, Not yet recruiting, Sponsor: Axon Neuroscience SE
- | AADvac1 / Axon Neurosci
Trial completion: FUNDAMANT: 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease (clinicaltrials.gov) - Mar 17, 2017
P1, N=25, Completed, Sponsor: Axon Neuroscience SE
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- AADvac1 / Axon Neurosci
Trial primary completion date: FUNDAMANT: 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease (clinicaltrials.gov) - Jul 19, 2016
P1, N=25, Active, not recruiting, Sponsor: Axon Neuroscience SE
Active, not recruiting --> Completed Trial primary completion date: May 2017 --> Aug 2016
- |||| AADvac1 / Axon Neurosci
Enrollment open, Trial initiation date: ADAMANT: 24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Mar 15, 2016
P2, N=185, Recruiting, Sponsor: Axon Neuroscience SE
Trial primary completion date: May 2017 --> Aug 2016 Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Mar 2016
- ||||| AADvac1 / Axon Neurosci
New P2 trial: ADAMANT: 24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease (clinicaltrials.gov) - Oct 23, 2015
P2, N=185, Not yet recruiting, Sponsor: Axon Neuroscience SE
- AADvac1 / Axon Neurosci
Enrollment closed: FUNDAMANT: 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease (clinicaltrials.gov) - May 28, 2015
P1, N=25, Active, not recruiting, Sponsor: Axon Neuroscience SE
Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Mar 2016 Recruiting --> Active, not recruiting
- | AADvac1 / Axon Neurosci
Trial completion: Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease (clinicaltrials.gov) - May 20, 2015
P1, N=30, Completed, Sponsor: Axon Neuroscience SE
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- AADvac1 / Axon Neurosci
Enrollment closed, Trial primary completion date: Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease (clinicaltrials.gov) - Oct 10, 2014
P1, N=30, Active, not recruiting, Sponsor: Axon Neuroscience SE
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Apr 2015
- AADvac1 / Axon Neurosci
Enrollment open: FUNDAMANT: 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease (clinicaltrials.gov) - Sep 12, 2014
P1, N=30, Recruiting, Sponsor: Axon Neuroscience SE
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Apr 2015 Not yet recruiting --> Recruiting
- | AADvac1 / Axon Neurosci
New P1 trial: FUNDAMANT: 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease (clinicaltrials.gov) - Jan 7, 2014
P1, N=30, Not yet recruiting, Sponsor: Axon Neuroscience SE
- AADvac1 / Axon Neurosci
Enrollment open: Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease (clinicaltrials.gov) - May 22, 2013
P1, N=30, Recruiting, Sponsor: Axon Neuroscience SE
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AADvac1 / Axon Neurosci
New P1 trial: Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease (clinicaltrials.gov) - May 7, 2013
P1, N=30, Recruiting, Sponsor: Axon Neuroscience SE